Long lasting octreotide LAR therapy in large cell neuroendocrine carcinoma (LCNEC) of the lung
In this article we report a case of a patient with large cell neuroendocrine carcinoma (LCNEC) of the lung. Patients with LCNEC usually have poor prognosis and the benefit of adjuvant chemotherapy for these patients has not been fully established. This case suggests that octreotide LAR, a somatostat...
Main Author: | Alfredo Butera |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd
2015-10-01
|
Series: | Clinical Management Issues |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1066 |
Similar Items
-
Prolonged progression‐free survival achieved by octreotide LAR plus transarterial embolization in low‐to‐intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden
by: Yiming Liu, et al.
Published: (2022-07-01) -
Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
by: Yau H, et al.
Published: (2017-12-01) -
Resected thymic large cell neuroendocrine carcinoma: report of a case
by: Hiromitsu Domen, et al.
Published: (2018-11-01) -
A case of colorectal large cell neuroendocrine carcinoma accompanied by disseminated peritoneal leiomyomatosis
by: Kunihiko Suga, et al.
Published: (2020-12-01) -
Role of high dose octreotide LAR for the treatment of GEP-NETs
by: Giulia M. Franchi, et al.
Published: (2009-03-01)